中华实用儿科临床杂志
中華實用兒科臨床雜誌
중화실용인과림상잡지
Journal of Applied Clinical Pediatrics
2015年
8期
627-630
,共4页
徐艳利%田庆玲%姜太一%庞保东%冯雪%庞琳%梁连春%孟一星%李辉
徐豔利%田慶玲%薑太一%龐保東%馮雪%龐琳%樑連春%孟一星%李輝
서염리%전경령%강태일%방보동%풍설%방림%량련춘%맹일성%리휘
雾化吸入%手足口病%重组人干扰素α1b%神经系统受累期
霧化吸入%手足口病%重組人榦擾素α1b%神經繫統受纍期
무화흡입%수족구병%중조인간우소α1b%신경계통수루기
Nebulization%Hand-foot-mouth disease%Human recombinant interferon α1 b%Nervous system complications
目的 评价雾化吸入重组人干扰素α1b对重症手足口病(神经系统受累期)患儿的疗效和安全性,为儿科合理用药提供科学依据.方法 采用随机、对照、多中心的设计方法,将3家医院重症手足口病患儿分为2组.对照组采用常规对症治疗,治疗组在此基础上雾化吸入重组人干扰素α1b注射液30 μg/次,2次/d,疗程5～7 d.并采用SPSS 17.0软件进行分析,比较2组患儿疗效.结果 2013年5至11月共66例患儿入组,与对照组比较,雾化吸入重组人干扰素α1b可显著缩短重症手足口病(神经受累期)患儿热程[治疗组(1.9±1.1)d,对照组(2.7±1.2)d,P＜0.05]、恢复进食时间[治疗组(3.9±1.4)d,对照组(4.9±1.6)d,P ＜0.05]和中枢神经系统症状持续时间[治疗组(2.6±1.1)d,对照组(3.2±1.0)d,P＜0.05],明显缓解易惊[治疗组(2.4±1.0)d,对照组(3.2±0.9)d,P＜0.05]和肢体抖动[治疗组(2.0±1.1)d,对照组(2.9±1.2)d,P＜0.05]的持续时间.对治疗组用药期间生命体征、血常规、血生化的观察和检查均未见不良反应.结论 雾化吸入人重组干扰素α1b可用于治疗小儿手足口病,能显著改善重症手足口病早期患儿的神经系统表现和其他临床表现,安全性良好.
目的 評價霧化吸入重組人榦擾素α1b對重癥手足口病(神經繫統受纍期)患兒的療效和安全性,為兒科閤理用藥提供科學依據.方法 採用隨機、對照、多中心的設計方法,將3傢醫院重癥手足口病患兒分為2組.對照組採用常規對癥治療,治療組在此基礎上霧化吸入重組人榦擾素α1b註射液30 μg/次,2次/d,療程5～7 d.併採用SPSS 17.0軟件進行分析,比較2組患兒療效.結果 2013年5至11月共66例患兒入組,與對照組比較,霧化吸入重組人榦擾素α1b可顯著縮短重癥手足口病(神經受纍期)患兒熱程[治療組(1.9±1.1)d,對照組(2.7±1.2)d,P＜0.05]、恢複進食時間[治療組(3.9±1.4)d,對照組(4.9±1.6)d,P ＜0.05]和中樞神經繫統癥狀持續時間[治療組(2.6±1.1)d,對照組(3.2±1.0)d,P＜0.05],明顯緩解易驚[治療組(2.4±1.0)d,對照組(3.2±0.9)d,P＜0.05]和肢體抖動[治療組(2.0±1.1)d,對照組(2.9±1.2)d,P＜0.05]的持續時間.對治療組用藥期間生命體徵、血常規、血生化的觀察和檢查均未見不良反應.結論 霧化吸入人重組榦擾素α1b可用于治療小兒手足口病,能顯著改善重癥手足口病早期患兒的神經繫統錶現和其他臨床錶現,安全性良好.
목적 평개무화흡입중조인간우소α1b대중증수족구병(신경계통수루기)환인적료효화안전성,위인과합리용약제공과학의거.방법 채용수궤、대조、다중심적설계방법,장3가의원중증수족구병환인분위2조.대조조채용상규대증치료,치료조재차기출상무화흡입중조인간우소α1b주사액30 μg/차,2차/d,료정5～7 d.병채용SPSS 17.0연건진행분석,비교2조환인료효.결과 2013년5지11월공66례환인입조,여대조조비교,무화흡입중조인간우소α1b가현저축단중증수족구병(신경수루기)환인열정[치료조(1.9±1.1)d,대조조(2.7±1.2)d,P＜0.05]、회복진식시간[치료조(3.9±1.4)d,대조조(4.9±1.6)d,P ＜0.05]화중추신경계통증상지속시간[치료조(2.6±1.1)d,대조조(3.2±1.0)d,P＜0.05],명현완해역량[치료조(2.4±1.0)d,대조조(3.2±0.9)d,P＜0.05]화지체두동[치료조(2.0±1.1)d,대조조(2.9±1.2)d,P＜0.05]적지속시간.대치료조용약기간생명체정、혈상규、혈생화적관찰화검사균미견불량반응.결론 무화흡입인중조간우소α1b가용우치료소인수족구병,능현저개선중증수족구병조기환인적신경계통표현화기타림상표현,안전성량호.
Objective To evaluate the efficacy and safety of nebulized recombinant human interferon α1b (IFN-α1b) for severe hand-foot-mouth disease (HFMD)children with central nervous system complications (CNSC).Methods This was a multi-center,prospective,cohort study.Severe HFMD children with CNSC from 3 hospitals were assigned to the control group with conventional therapy,and therapeutic group based on convetional therapy with nebulization of recombinant human IFN-α1 b,30 μg twice each day,for 5-7 days.The curative effect between 2 groups was compared by using SPSS 17.0 software.Results Sixty-six cases were enrolled from May to November 2013.Compared with conventional tberapy,the treatment of nebulized IFN-α1 b could significantly reduce the duration of fever[treatment group (1.9 ± 1.1) d vs control group (2.7 ± 1.2) d,P ＜ 0.05],the recovery time of food intake [treatment group (3.9 ± 1.4) d vs control group (4.9 ± 1.6) d,P ＜ 0.05] and the duration of the central nervous system syndrome [(2.6 ± 1.1) d vs (3.2 ± 1.0) d,P ＜ 0.05],especially shorten the duration of convulsion [treatment group (2.4 ± 1.0) d vs control group (3.2 ± 0.9) d,P ＜ 0.05] and myoclonic jerk [(2.0 ± 1.1) vs (2.9 ± 1.2) d,P ＜ 0.05].Vital signs,routine hematological and biochemical parameters were monitored and no adverse effect was observed during the treatment.Conclusion Nebulization of human recombinant IFN-α1 b can significantly and safely alleviate early clinical syndrome of severe HFMD children.
